{"organizations": [], "uuid": "f408d10a280c91a85f5d140e3ceb7079dd64fae1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180508.html", "section_title": "Archive News &amp; Video for Tuesday, 08 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-vifor-pharma-says-us-fda-approves/brief-vifor-pharma-says-us-fda-approves-use-of-veltassa-with-or-without-food-idUSASO0004HF", "country": "US", "domain_rank": 408, "title": "BRIEF-Vifor Pharma Says US FDA Approves Use Of Veltassa With Or Without Food", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.818, "site_type": "news", "published": "2018-05-08T13:14:00.000+03:00", "replies_count": 0, "uuid": "f408d10a280c91a85f5d140e3ceb7079dd64fae1"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-vifor-pharma-says-us-fda-approves/brief-vifor-pharma-says-us-fda-approves-use-of-veltassa-with-or-without-food-idUSASO0004HF", "ord_in_thread": 0, "title": "BRIEF-Vifor Pharma Says US FDA Approves Use Of Veltassa With Or Without Food", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "vifor pharma ag", "sentiment": "negative"}, {"name": "brief-vifor pharma says us fda", "sentiment": "negative"}, {"name": "harma ag", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 8 (Reuters) - Vifor Pharma AG:\n* US FDA APPROVES USE OF VELTASSAÂ® WITH OR WITHOUT FOOD * VIFOR PHARMA AG - UPDATED LABEL MAY ALLOW FOR INCREASED DOSING FLEXIBILITY FOR PATIENTS WITH HYPERKALAEMIA Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-08T13:14:00.000+03:00", "crawled": "2018-05-09T12:46:02.009+03:00", "highlightTitle": ""}